The FDA and EMA have approved until now three GLP-1 receptor agonists for treatment of obesity: liraglutide (2015, Novo Nordisk), semaglutide (2021, Novo Nordisk), and tirzepatide (2022, Eli Lilly). The gene discussed is GLP1R; the disease is obesity disorder.